<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01322789</url>
  </required_header>
  <id_info>
    <org_study_id>HCFMRPUSP 2</org_study_id>
    <secondary_id>CNPQ 552266/2005-1</secondary_id>
    <nct_id>NCT01322789</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients</brief_title>
  <official_title>Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: Conselho Nacional de Ética em Pesquisa</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes mellitus results from the autoimmune destruction of the insulin producing
      pancreatic β-cells. The autoimmune response begins months or even years before the
      presentation of hyperglycemic symptoms. Previous studies with other autoimmune diseases or
      acute inflammatory diseases testing the effect of the infusion of mesenchymal stem cells
      showed promising results in regulating immune system and promoting some degree of disease
      control. The aim of our study is to determine the safety and efficacy of intravenous
      infusions of mesenchymal stem cells in newly diagnosed type 1 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 12 to 35 years old with type I diabetes mellitus proved by anti-pancreatic
      beta cell antibodies and recently diagnosed (less than 6 weeks) will be included in this
      study. First, bone marrow derived adult mesenchymal stem cells are collected from a first
      degree relative and cultured. After that, the patient receive 4 intravenous infusions 1 week
      apart followed by 4 infusion 4 months apart.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>AUC C-peptide levels during mixed meal tolerance test</measure>
    <time_frame>pré-treatment, 6 months, 12 months and then yearly (course of study 7 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Every 6 months until death</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The process of analyzing safety data is made daily based on clinical interview, frequent physical examination and general laboratory findings weekly from the first stem cell infusion until 60 months after the last infusion. Chest X-ray will be performed in days 100, 180, 270, 360 after the lest infusion and then every 6 months. Fecal occult blood, alpha pheto protein, beta-human chorionic gonadotropin, carcino-embrionary antigen, abdomen ultrasound will be performed in month 6 and 12 after the last infusion and then yearly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily insulin use</measure>
    <time_frame>Daily (course of study is 7 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GAD titres</measure>
    <time_frame>Every 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic reconstitution parameters</measure>
    <time_frame>Yearly (course of study is 7 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Intravenous mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous Mesenchymal stem cell infusion</intervention_name>
    <description>Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart</description>
    <arm_group_label>Intravenous mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus diagnosed by clinical/metabolic parameters and positive
             anti-GAD antibodies

          -  Less than 6 weeks from diagnosis

        Exclusion Criteria:

          -  Previous diabetic ketoacidosis

          -  Pregnancy

          -  Severe psychiatric disorder

          -  Severe organic impairment (renal, hepatic, cardiac, pulmonary)

          -  Active infectious disease

          -  Previous or present neoplastic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Voltarelli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, School of Medicine of Ribeirão Preto, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos E Couri, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, School of Medicine of Ribeirão Preto, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio Voltarelli, MD, PhD</last_name>
    <phone>+55 16 2101 9369</phone>
    <email>jcvoltar@fmrp.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos E Couri</last_name>
    <phone>+5516 91495151</phone>
    <email>ce.couri@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio C Voltarelli, MD, PhD</last_name>
      <phone>+551621019369</phone>
      <email>jcvoltar@fmrp.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Carlos E Couri, MD, PhD</last_name>
      <phone>+551691495151</phone>
      <email>ce.couri@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Julio Voltarelli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos E Couri, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>March 24, 2011</lastchanged_date>
  <firstreceived_date>December 7, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Júlio Cesar Voltarelli</name_title>
    <organization>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</organization>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Autoimmune diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
</clinical_study>
